Menu Back toRealizing the Value of Digital Biomarkers Across the Product Lifecycle

DIA 2021 Global Annual Meeting

Realizing the Value of Digital Biomarkers Across the Product Lifecycle

Session Chair(s)

John James Hall, PhD

John James Hall, PhD

  • Senior Vice President, Europe and AsiaPac
  • CluePoints, Belgium
How should your organization be using digital biomarkers? Do you have a roadmap for digital biomarkers? This session will share examples of best practices of how digital biomarkers can be used to add value across the product lifecycle.
Learning Objective : Demonstrate the basics of a digital biomarker and the value it can add to diagnostics and therapies across their lifecycle; Evaluate challenges in the development, deployment and reimbursement of digital biomarkers; Identify pathways to integrate digital biomarkers into their pipelines; Define the questions that organizations should answer before beginning digital biomarker development.


Tim  McCarthy, PhD, MBA


Tim McCarthy, PhD, MBA

  • Head, Digital Medicine and Translational Imaging
  • Pfizer Inc, United States
Diane  Stephenson, PhD


Diane Stephenson, PhD

  • Executive Director
  • Critical Path Institute, United States
Matthew  Bonam


Matthew Bonam

  • Global Head, BioPharma R&D Digital Health
  • AstraZeneca, United Kingdom
Mo  Ali


Mo Ali

  • Vice President, Digital Analytics and Performance
  • GlaxoSmithKline, United States